vs
Side-by-side financial comparison of INDEPENDENT BANK CORP (INDB) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
INDEPENDENT BANK CORP is the larger business by last-quarter revenue ($212.5M vs $177.4M, roughly 1.2× Pacira BioSciences, Inc.). INDEPENDENT BANK CORP runs the higher net margin — 35.5% vs 1.6%, a 33.8% gap on every dollar of revenue. On growth, INDEPENDENT BANK CORP posted the faster year-over-year revenue change (46.9% vs 5.0%). Over the past eight quarters, INDEPENDENT BANK CORP's revenue compounded faster (24.3% CAGR vs -0.2%).
Independent Bank is a bank headquartered in Grand Rapids, Michigan. The bank has 62 branches, all of which are in Michigan.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
INDB vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $212.5M | $177.4M |
| Net Profit | $75.3M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 35.5% | 1.6% |
| Revenue YoY | 46.9% | 5.0% |
| Net Profit YoY | 50.6% | — |
| EPS (diluted) | $1.51 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $212.5M | $196.9M | ||
| Q3 25 | $203.3M | $179.5M | ||
| Q2 25 | $147.5M | $181.1M | ||
| Q1 25 | $145.5M | $168.9M | ||
| Q4 24 | $144.7M | $187.3M | ||
| Q3 24 | $141.7M | $168.6M | ||
| Q2 24 | $137.9M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $75.3M | — | ||
| Q3 25 | $34.3M | $5.4M | ||
| Q2 25 | $51.1M | $-4.8M | ||
| Q1 25 | $44.4M | $4.8M | ||
| Q4 24 | $50.0M | — | ||
| Q3 24 | $42.9M | $-143.5M | ||
| Q2 24 | $51.3M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | 21.8% | 3.5% | ||
| Q2 25 | 44.6% | 4.7% | ||
| Q1 25 | 39.3% | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | 39.0% | -82.8% | ||
| Q2 24 | 48.1% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 35.5% | — | ||
| Q3 25 | 16.8% | 3.0% | ||
| Q2 25 | 34.6% | -2.7% | ||
| Q1 25 | 30.5% | 2.8% | ||
| Q4 24 | 34.6% | — | ||
| Q3 24 | 30.3% | -85.1% | ||
| Q2 24 | 37.2% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $1.51 | $0.05 | ||
| Q3 25 | $0.69 | $0.12 | ||
| Q2 25 | $1.20 | $-0.11 | ||
| Q1 25 | $1.04 | $0.10 | ||
| Q4 24 | $1.18 | $0.38 | ||
| Q3 24 | $1.01 | $-3.11 | ||
| Q2 24 | $1.21 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.6B | $653.9M |
| Total Assets | $24.9B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $3.6B | $693.1M | ||
| Q3 25 | $3.5B | $727.2M | ||
| Q2 25 | $3.1B | $757.8M | ||
| Q1 25 | $3.0B | $798.5M | ||
| Q4 24 | $3.0B | $778.3M | ||
| Q3 24 | $3.0B | $749.6M | ||
| Q2 24 | $2.9B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $24.9B | $1.3B | ||
| Q3 25 | $25.0B | $1.3B | ||
| Q2 25 | $20.0B | $1.5B | ||
| Q1 25 | $19.9B | $1.6B | ||
| Q4 24 | $19.4B | $1.6B | ||
| Q3 24 | $19.4B | $1.5B | ||
| Q2 24 | $19.4B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $78.9M | — |
| Free Cash FlowOCF − Capex | $75.5M | — |
| FCF MarginFCF / Revenue | 35.5% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | 1.05× | — |
| TTM Free Cash FlowTrailing 4 quarters | $239.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $78.9M | $43.7M | ||
| Q3 25 | $52.2M | $60.8M | ||
| Q2 25 | $106.7M | $12.0M | ||
| Q1 25 | $13.3M | $35.5M | ||
| Q4 24 | $42.9M | $33.1M | ||
| Q3 24 | $70.2M | $53.9M | ||
| Q2 24 | $65.6M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $75.5M | $43.5M | ||
| Q3 25 | $49.7M | $57.0M | ||
| Q2 25 | $102.5M | $9.3M | ||
| Q1 25 | $11.3M | $26.9M | ||
| Q4 24 | $36.5M | $31.0M | ||
| Q3 24 | $64.4M | $49.8M | ||
| Q2 24 | $61.9M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 35.5% | 22.1% | ||
| Q3 25 | 24.4% | 31.7% | ||
| Q2 25 | 69.5% | 5.1% | ||
| Q1 25 | 7.8% | 15.9% | ||
| Q4 24 | 25.2% | 16.6% | ||
| Q3 24 | 45.4% | 29.6% | ||
| Q2 24 | 44.9% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | 0.1% | ||
| Q3 25 | 1.2% | 2.2% | ||
| Q2 25 | 2.9% | 1.5% | ||
| Q1 25 | 1.4% | 5.1% | ||
| Q4 24 | 4.4% | 1.1% | ||
| Q3 24 | 4.1% | 2.4% | ||
| Q2 24 | 2.7% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.05× | — | ||
| Q3 25 | 1.52× | 11.20× | ||
| Q2 25 | 2.09× | — | ||
| Q1 25 | 0.30× | 7.37× | ||
| Q4 24 | 0.86× | — | ||
| Q3 24 | 1.64× | — | ||
| Q2 24 | 1.28× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INDB
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
